ABUS vs AME
Arbutus Biopharma Corp (ABUS) versus Ametek Inc (AME) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Ametek Inc (AME) is a specialty industrial machinery company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported AME revenue for 2024-12-31 was $6.94B. Net income was $1.38B. Revenue was up 5.2% from 2023-12-31 to 2024-12-31. AME currently screens at market cap $42.11B and trailing P/E 29.9.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. AME currently screens at market cap $42.11B and trailing P/E 29.9.
Not investment advice. Open the ABUS and AME stock pages for the full models.
Not investment advice.